ArticleThe Journal of antimicrobial chemotherapy2025
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incidence of Cefotaxime-Resistant Haemophilus influenzae Is Linked to Regional Consumption of Oral Aminopenicillins and Parenteral Third-Generation Cephalosporins in Norway.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Understanding the burden and impact of methicillin-resistantFrontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo determine the antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) Streptococcus pneumoniae and Haemophilus influenzae isolates from Italy and Spain, 2018-21.
methodsMICs were determined by CLSI broth microdilution, and susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
resultsA total of 77 S. pneumoniae and 249 H. influenzae were collected from Italy and 176 S. pneumoniae and 275 H. influenzae from Spain. Approximately 65% of pneumococci were penicillin-susceptible by CLSI oral or EUCAST low-dose breakpoints; by EUCAST high-dose or CLSI intravenous administration, 92.2%/95.5% (Italy/Spain) were susceptible. In Italy, 71.4% to 89.6% susceptibility (CLSI) was observed to amoxicillin/clavulanic acid, amoxicillin and most cephalosporins. Cefaclor, tetracyclines, macrolides and trimethoprim/sulfamethoxazole were less active against Italian (51.9%-67.5% susceptible) versus Spanish (67.0%-81.2% susceptible) isolates. The most potent antibiotics were fluoroquinolones (≥99.4%, excluding EUCAST low-dose). Most H. influenzae isolates were β-lactamase negative with a few ampicillin-resistant isolates (CLSI: 0.5% Italy, 3.1% Spain). Rates of β-lactamase positivity were 14.1% (Italy) and 17.1% (Spain). Susceptibility was >90% (CLSI) except for ampicillin (82.7% Italy, 81.1% Spain) and trimethoprim/sulfamethoxazole (71.1% Italy, 68.0% Spain). Susceptibility by EUCAST was similar to CLSI, except for cefuroxime (82.3% Italy, 87.3% Spain susceptible, increased exposure versus 100% by CLSI).
conclusionsSusceptibility of S. pneumoniae to many antibiotics was low in both countries, with susceptibility > 90% observed only with high-dose penicillin and fluoroquinolones (CLSI and EUCAST) and high-dose amoxicillin or amoxicillin/clavulanic acid (PK/PD). Higher susceptibility was seen with H. influenzae in both countries. Continued surveillance of antimicrobial resistance is important for guiding therapy of CA-RTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.